Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company ...(ion during 2006. The decrease in R&D .....)

expenses was primarily attributable to the CETHRIN license fee of $10

million in 2006.

-- General and administrative (G&A) expenses were $8.4 million in 2007 as

compared to $7.9 million in 2006. The increase in G&A expenses was

primarily related to higher commercialization and communication costs

and higher headcount offset by lower costs related to our collaboration

and fundraising efforts.

Conference Call Access Information

The Company will host a conference call to discuss results on, April 1,

2008, at 10:00 a.m. Eastern Daylight Time. The call can be accessed by

dialing dial 877-718-5104 (or 719-325-4843 for international

participants). The participant pass code for this conference call is

7767549. Please dial in 5 to 10 minutes prior to the scheduled start

time. A replay of the call will be posted on the Investor Relations

section of the website, http://www.alseres.com, within 48 hours following

the conference call and will be available through Tuesday, April 15, 2008.

About Alseres

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. CETHRIN, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative ther
'/>"/>